Ian Watson

Dr. Watson is a member of the Rosalind and Morris Goodman Cancer Institute and is an Associate Professor in the Department of Biochemistry at McGill University.

 His research focuses on understanding how mutated genes identified in next-generation sequencing analyses promote cutaneous melanoma progression and response to therapy. His lab utilizes inter-disciplinary approaches combining unbiased molecular characterization of melanoma tumors, rapid development of preclinical models using genome editing technology, and bioinformatic approaches. He is co-PI of the Montreal Cancer Consortium Terry Fox Research Institute Marathon of Hope Pilot project whose goal is understanding mechanisms of anti-cancer therapy response, resistance and toxicity, with a focus on immunotherapy.